Lev-Ran A
Am J Dis Child. 1977 Jun;131(6):648-9. doi: 10.1001/archpedi.1977.02120190042008.
We observed 40 patients with 45,X gonadal dysgenesis from the age of 13 to 15 years until the age of 18 to 21 years. The ultimate height of the 12 nontreated patients was 143.2 cm. Of 15 patients treated with nandrolone phenpropionate or methandrostenolone, the ultimate height was 143.3 cm, and of 13 patients treated with ethinyl estradiol, the height reached was 144.1 cm. The mean height of ten patients first seen at the age of 25 to 31 years was 140.1 cm. The mean height at any age was almost identical in all the groups. The growth velocity was somewhat accelerated by anabolic steroids and to a lesser extent, by estrogens only during the first year of therapy, and this did not influence the ultimate height. We saw no deleterious effects of the estrogens. In all the groups, there were patients who grew for some time at rates of up to 4 to 6 cm/yr. Therefore, long-term follow-up studies are needed for the evaluation of the effects of any treatment.
我们观察了40例45,X性腺发育不全患者，年龄从13至15岁到18至21岁。12例未接受治疗患者的最终身高为143.2厘米。15例接受苯丙酸诺龙或甲睾酮治疗的患者，最终身高为143.3厘米，13例接受炔雌醇治疗的患者，达到的身高为144.1厘米。首次就诊年龄在25至31岁的10例患者的平均身高为140.1厘米。所有组在任何年龄的平均身高几乎相同。合成代谢类固醇在一定程度上加快了生长速度，雌激素仅在治疗的第一年有较小程度的加快，且这并未影响最终身高。我们未发现雌激素有有害影响。在所有组中，都有患者在一段时间内以每年4至6厘米的速度生长。因此，需要进行长期随访研究以评估任何治疗的效果。
